Selma Boussen

Dr. Boussen is a seasoned professional in clinical development having served as Global Head of Clinical and Medical Department (LFB Biotechnologies), European Medical Affairs Director (Pharmion Corp., Ortho Biotech Europe, Searle Monsanto), European Medical Marketing Director (Pharmacia Corp.), and Medical Director (Amgen Europe). She has managed and lead over 20 clinical development programs in all phases of development including post marketing. Her primary therapeutic focus has been with oncology and hematology products, including Vidaza, Thalidomide, Refludan, Satraplatin, Eprex, Velcade, Celebrex, Abelcept, and Neupogen. Dr. Boussen received her PhD in Human Genetics from the Faculte de Sciences, Tunis and her MD from the Faculte de Medecine Cochin-Port Royal, Paris.